

## Bortezomib-based immunosuppression after reduced-intensity conditioning hematopoietic stem cell transplantation: randomized phase II results

John Koreth,<sup>1</sup> Haesook T. Kim,<sup>2</sup> Paulina B. Lange,<sup>1</sup> Samuel J. Poryanda,<sup>1</sup> Carol G. Reynolds,<sup>1</sup> Sharmila Chamling Rai,<sup>1</sup> Philippe Armand,<sup>1</sup> Corey S. Cutler,<sup>1</sup> Vincent T. Ho,<sup>1</sup> Brett Glotzbecker,<sup>1</sup> Rushdia Yusuf,<sup>1</sup> Sarah Nikiforow,<sup>1</sup> Yi-Bin Chen,<sup>3</sup> Bi-malangshu Dey,<sup>3</sup> Malgorzata McMasters,<sup>4</sup> Jerome Ritz,<sup>1</sup> Bruce R. Blazar,<sup>5</sup> Robert J. Soiffer,<sup>1</sup> Joseph H. Antin<sup>1</sup> and Edwin P. Alyea III<sup>1</sup>

<sup>1</sup>Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; <sup>2</sup>Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute and Harvard School of Public Health, Boston, MA; <sup>3</sup>Massachusetts General Hospital Cancer Center, Boston, MA; <sup>4</sup>Beth Israel Deaconess Hospital Cancer Center, Boston, MA and <sup>5</sup>University of Minnesota Masonic Cancer Center and Department of Pediatrics, Division of Blood and Marrow Transplantation, Minneapolis, MN, USA

©2018 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2017.176859

Received: July 18, 2017.

Accepted: January 10, 2018.

Pre-published: January 11, 2018.

Correspondence: john\_koreth@dfci.harvard.edu

---

**Supplementary Table A:** Summary of aGVHD Outcome by HLA-match

Legend:

aGVHD: acute graft-versus-host disease

Cum. Incid.: cumulative incidence

CI: confidence interval

**Supplementary Figure 1:** Cumulative Incidence of Acute GVHD by Treatment Arm and HLA-match. (A): Grade II-IV acute GVHD for 8/8 match; (B) Severe Grade III-IV acute GVHD for 8/8 match; (C) Grade II-IV acute GVHD for 7/8 match; and (D) Severe Grade III-IV acute GVHD for 7/8 match. Acute GVHD events after relapse with IS taper were included

Black indicates arm A (tac/mtx); red indicates arm B (bort/tac/mtx); and blue indicates arm C (bort/sir/tac). Gray test was used for group comparison.

Legend:

Tac: tacrolimus

Mtx: methotrexate

Bort: bortezomib

Sir: sirolimus

Supplementary Table A. Summary of aGVHD outcome by HLA match.

(A) aGVHD after relapse with IS taper included

	Arm			p-value		
	A (Tac/MTX)	B (Bort/Tac/MTX)	C (Bort/Sir/Tac)	A vs B	A vs C	A vs (B&C)
D180 Cum. Inc. of grade II-IV aGVHD						
8/8 matched (95% CI)	33% (17, 49)	16% (6, 30)	19% (7, 34)	0.1	0.21	0.08
7/8 matched (95% CI)	33% (9, 60)	69% (34, 88)	27% (8, 51)	0.16	0.92	0.42
D180 Cum Inc of grade III-IV aGVHD						
8/8 matched (95% CI)	0% (-)	6% (1.1, 18)	9% (2.3, 23)	0.49	0.27	0.33
7/8 matched (95% CI)	8% (0.4, 32)	15% (2.2, 40)	27% (8, 51)	0.93	0.19	0.43

(B) aGVHD after relapse with IS taper excluded

D180 Cum. Inc. of grade II-IV aGVHD						
8/8 matched (95% CI)	33% (17, 49)	13% (4, 27)	16% (6, 30)	0.046	0.13	0.03
7/8 matched (95% CI)	33% (9, 60)	69% (34, 88)	13% (2, 36)	0.16	0.59	0.66
D180 Cum. Inc. of grade III-IV aGVHD						
8/8 matched (95% CI)	0% (-)	6% (1.1, 18)	9% (2.3, 23)	0.49	0.27	0.33
7/8 matched (95% CI)	8% (0.4, 32)	15% (2.2, 40)	13% (2, 36)	0.93	0.53	0.72

Gray test was used for group comparison

Figure S1. Cumulative Incidence of Acute GVHD by Treatment Arm and HLA match.

